New Data Presented at SABCS^® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score^® Test to Inform Clinical Decision-making

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX^® Test

New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients

Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection

New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening  

Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45

JAMIE FOXX, STAND UP TO CANCER AND EXACT SCIENCES LAUNCH PSA TO INCREASE AWARENESS OF COLORECTAL CANCER

The Truth About Cancer: Debunking Five Myths about the Big C

$10 MILLION GRANT FROM EXACT SCIENCES TO SUPPORT STAND UP TO CANCER INITIATIVE TO IMPROVE COLORECTAL CANCER SCREENING AND PREVENTION